Our mission is to deliver the greatest possible impact to people through mRNA medicines.
Cambridge, MA
Joined December 2013
- Tweets2.9K
- Following541
- Followers145K
- Likes522
With our partners at @Merck, we announced detailed results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized neoantigen therapy, in combination with pembrolizumab, in patients with completely resected stage IIB-IV melanoma.
Presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026, these findings offer important insights into the potential of individualized cancer treatment.
Read more: modernatx.com/recapping-the-…
Today we announced detailed positive results from the Phase 3 INTerpath-001 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab), @Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage IIB-IV) following complete resection.
These late-breaking results will be presented during a Presidential Symposium at the 2026 European Society for Medical Oncology (@myESMO) Congress.
Read more: feeds.issuerdirect.com/news-…
Today, we announced the addition of a Chief Operating Officer role to support the growing scale and diversification of our company.
Juan Andres will return to Moderna as Chief Operating Officer, effective October 5, 2026. In this role, he will help drive focus, prioritization and execution across the Company while leading our manufacturing organization. Juan previously spent nearly six years at Moderna, serving in several leadership roles before retiring from the Company in 2023.
Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, has decided to retire from Moderna. Since joining in 2022, Jerh has helped evolve our manufacturing footprint for an endemic vaccine market, advance our capabilities in the UK, Canada and Australia, and establish the manufacturing model to support intismeran autogene, our investigational individualized neoantigen therapy.
We’re pleased to welcome Juan back to Moderna and grateful to Jerh for his leadership and contributions.
feeds.issuerdirect.com/news-…
Today we announced that three abstracts on intismeran autogene, our investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (@myESMO) Congress 2026, which will be held October 23–27 in Madrid, Spain.
Read more: feeds.issuerdirect.com/news-…
#ESMO26
Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19.
Read more: feeds.issuerdirect.com/news-…
Along with our partners at @Merck, we announced positive results from the Phase 3 INTerpath-001 study of intismeran autogene, our investigational individualized neoantigen therapy, in combination with pembrolizumab as adjuvant treatment in patients with completely resected Stage IIB-IV melanoma. This marks the first and only combination regimen to demonstrate a clinically meaningful improvement over pembrolizumab alone, a current standard-of-care for these patients.
In our latest IR Insights, members of our executive team sat down to reflect on what this means: modernatx.com/ir-insights-ph…
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:
Today we announced that the U.S. Food and Drug Administration has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee supporting mFLUSIVA for adults 50 years of age and older.
Read more: feeds.issuerdirect.com/news-…
Today we announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, our investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus disease.
Read more: feeds.issuerdirect.com/news-…
Today we reported financial results and provided business updates for the second quarter of 2026.
Read more: feeds.issuerdirect.com/news-…
Today we announced the dosing of the first U.S. participant in our Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors.
Read more: feeds.issuerdirect.com/news-…
At Moderna, our Mission is to deliver the greatest possible impact to people through mRNA medicines. In pursuit of this, we remain focused on advancing our science, supporting our people, and delivering for patients, communities, and the environment.
Our latest Impacting Human Health Report reflects how we are continuing to turn scientific progress into meaningful impact while helping shape a healthier future for people around the world.
Read the full report: static.modernatx.com/pm/6cef…
Today we announced the appointment of Michael McDonnell to our Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.
Read more: feeds.issuerdirect.com/news-…
Yesterday, Moderna announced research and early development updates at our Science Day event.
Members of our executive team sat down to provide more insight into our strategy that balances near-term growth with long-term innovation. Watch our latest IR Insights video to learn more: modernatx.com/ir-insights-sc…
At our Science Day event, we shared how we're building Moderna for the next decade and beyond.
In his latest blog post, our CEO Stéphane Bancel outlines our three-horizon strategy—executing on today's commercial opportunities while advancing new modalities and investing in science, AI and platform innovation that will help shape the next generation of mRNA medicines.
Read more: modernatx.com/science-day
